Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $20.2 Million - $25 Million
-271,400 Reduced 83.25%
54,600 $4.5 Million
Q1 2024

May 15, 2024

BUY
$83.81 - $99.0 $24.5 Million - $28.9 Million
292,000 Added 858.82%
326,000 $28.5 Million
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $769,822 - $994,951
10,100 Added 42.26%
34,000 $3.28 Million
Q2 2023

Aug 14, 2023

SELL
$86.68 - $100.3 $7.53 Million - $8.72 Million
-86,900 Reduced 78.43%
23,900 $2.07 Million
Q1 2023

May 12, 2023

BUY
$87.74 - $117.27 $3.11 Million - $4.16 Million
35,500 Added 47.14%
110,800 $10.8 Million
Q3 2022

Nov 14, 2022

BUY
$82.16 - $96.94 $3.9 Million - $4.6 Million
47,500 Added 170.86%
75,300 $6.38 Million
Q2 2022

Aug 12, 2022

BUY
$71.48 - $86.85 $1.87 Million - $2.27 Million
26,100 Added 1535.29%
27,800 $2.3 Million
Q4 2021

Feb 08, 2022

BUY
$71.72 - $91.47 $14,344 - $18,294
200 Added 13.33%
1,700 $150,000
Q2 2021

Sep 13, 2021

BUY
$75.51 - $84.79 $113,265 - $127,185
1,500 New
1,500 $125,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.